Arine, the leader in AI-driven medication intelligence, announced a Series C funding round. Town Hall Ventures, known for backing transformative healthcare solutions, led the round with participation from Kaiser Permanente Ventures and other existing investors. This $30 million dollar round brings Arine’s total funding to $66 million and cements Arine’s position at the forefront of healthcare innovation, empowering the company to accelerate its mission of redefining medication management across the healthcare continuum at a time when the industry faces unprecedented financial and regulatory pressures.
“This is a defining moment for healthcare and for Arine,” said Yoona Kim, PharmD, PhD, CEO and co-founder of Arine. “Mounting cost pressures and sweeping policy changes are forcing the industry to rethink how care is delivered. Amid these challenges, medications have emerged as one of the most powerful—and underleveraged—tools to improve outcomes and control costs. With this new capital, we’re expanding our ability to deliver meaningful impact for each patient, when the system needs it most.”
Arine’s AI platform focuses on the critical area of medication optimization, delivering scalable, personalized, and cost-effective medication therapy that is essential to success in value-based care. Designed for leading health plan and risk-bearing providers, Arine’s platform leverages large, diverse datasets to identify the right individuals, recommend the most effective interventions, and continuously measure impact to ensure meaningful outcomes.
Arine’s approach has consistently achieved >10% in total cost savings and >40% reduction in hospitalizations. These outcomes have led to >100% growth in the last year and an average contract expansion of 80% with existing clients.
Also Read: Seek Labs Maps Measles with BioSeeker™, Eyes First Antiviral
“The rising cost of medications and the consequences of suboptimal medication use presents significant opportunities for innovation, particularly using AI. What sets Arine apart is not just its transformative technology, but its ability to consistently deliver measurable value for clients across populations, especially in underserved communities. The company’s phenomenal leadership team combines deep clinical and AI expertise with a bold vision for the future,” said Andy Slavitt, General Partner at Town Hall Ventures. “Their platform is not just solving today’s problems—it’s anticipating tomorrow’s challenges. We’re proud to support Arine as they drive the next wave of healthcare innovation.”
“We’ve been partnering with Arine since 2020, and year after year, the value has been clear,” said Caroline Carney, MD, MSc, FAPA, FAPM, CPHQ, President and Chief Medical Officer at Magellan Health. “Arine continues to expand the capabilities of their platform in ways that drive even greater impact—advancing evidence-based quality, improving patient-centered outcomes, and delivering meaningful cost savings. It’s that ongoing evolution that makes them such a valuable long-term partner.”
With the new funding, Arine will focus on several key areas to meet evolving industry needs. Arine plans to expand its capabilities in specialty pharmacy management — a fast-growing and costly area of healthcare. At the same time, the company is accelerating AI innovation to automate high-volume, low-complexity tasks, allowing providers to focus more on direct patient care. Arine will also continue to integrate comprehensive data to further personalize medication therapy. Together, these advancements expand Arine’s impact and set a new standard for how technology can drive scalable, meaningful change in healthcare.
Source: PRNewswire
